Dual antiplatelet therapy in recurrent stroke prevention: do the benefits outweigh the risks?

Commentary on: Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual-versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013;159:463–70.[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Dual antiplatelet therapy (DAT) has yet to prove advantageous when taking into account the net risks and benefits of longer term administration. The primary drawback is the risk of bleeding complications, including intracranial haemorrhage and gastrointestinal bleeding.1 ,2 However, shorter term combination therapy after transient ischaemic attack (TIA) has been shown to be efficacious and safe.3 ,4 This study assessed seven randomised controlled trials, comprising 39 574 patients and comparing dual versus single antiplatelet therapies. Medications used included aspirin (50–325 mg daily), clopidogrel (75 mg daily), aspirin plus dipyridamole (50/400 mg daily) … [1]: {openurl}?query=rft.jtitle%253DAnn%2BIntern%2BMed%26rft.volume%253D159%26rft.spage%253D463%26rft_id%253Dinfo%253Adoi%252F10.7326%252F0003-4819-159-7-201310010-00006%26rft_id%253Dinfo%253Apmid%252F24081287%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.7326/0003-4819-159-7-201310010-00006&link_type=DOI [3]: /lookup/external-ref?access_num=24081287&link_type=MED&atom=%2Febmed%2F19%2F4%2F137.atom [4]: /lookup/external-ref?access_num=000325628000004&link_type=ISI

[1]  P. Gorelick,et al.  Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack , 2022 .

[2]  J. Saver,et al.  Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet Therapy Among Patients With Ischemic Stroke , 2013, Annals of Internal Medicine.

[3]  P. Gorelick,et al.  Advances in Our Understanding of “Resistance” to Antiplatelet Agents for Prevention of Ischemic Stroke , 2013, Stroke research and treatment.

[4]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[5]  C. Coffey,et al.  Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. , 2012, The New England journal of medicine.

[6]  P. Rothwell,et al.  Population-based study of risk and predictors of stroke in the first few hours after a TIA , 2009, Neurology.

[7]  H. Adams,et al.  Use of antiplatelet agents for prevention of ischemic stroke. , 2008, Neurologic clinics.

[8]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial , 2004 .

[9]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[10]  Sean I. Savitz,et al.  Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis , 2012 .